| Uveitis
Hyrimoz vs Yutiq
Side-by-side clinical, coverage, and cost comparison for uveitis.Deep comparison between: Hyrimoz vs Yutiq with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsYutiq has a higher rate of injection site reactions vs Hyrimoz based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Yutiq but not Hyrimoz, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Hyrimoz
Yutiq
At A Glance
SC injection
Every other week
TNF-alpha antagonist
Intravitreal injection
Single implant (36-month release)
Corticosteroid
Indications
- Rheumatoid Arthritis
- Juvenile rheumatoid arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis Vulgaris
- Hidradenitis
- Uveitis
- Uveitis
Dosing
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.
Juvenile rheumatoid arthritis Weight-based SC dosing every other week for patients >=2 years: 10 mg (10 to <15 kg), 20 mg (15 to <30 kg), or 40 mg (>=30 kg); same dosing applies to pediatric uveitis patients.
Crohn Disease Adults: 160 mg on Day 1, 80 mg on Day 15, then 40 mg SC every other week starting Day 29; pediatric patients >=6 years receive weight-based loading doses followed by 20 or 40 mg every other week.
Ulcerative Colitis Adults: 160 mg on Day 1, 80 mg on Day 15, then 40 mg SC every other week starting Day 29; discontinue if no clinical remission by Day 57.
Psoriasis Vulgaris, Uveitis 80 mg initial SC dose, then 40 mg every other week starting one week after initial dose.
Hidradenitis Adults: 160 mg Day 1, 80 mg Day 15, then 40 mg every week or 80 mg every other week SC starting Day 29; adolescents >=12 years receive weight-based dosing (80 mg Day 1 for 30 to <60 kg, or 160 mg Day 1 for >=60 kg).
Uveitis Single intravitreal implant (0.18 mg fluocinolone acetonide) injected under aseptic conditions into the vitreous, optimally placed inferior to the optic disc and posterior to the equator (4 mm inferotemporal from the limbus); monitor for IOP elevation and endophthalmitis following injection.
Contraindications
—
- Active or suspected ocular or periocular infections, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases
- Known hypersensitivity to any components of this product
Adverse Reactions
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, sinusitis, nausea, abdominal pain, back pain, urinary tract infection, flu syndrome, accidental injury, hypertension.
Serious Serious infections (pneumonia, septic arthritis, erysipelas, cellulitis, diverticulitis, pyelonephritis), malignancies, hypersensitivity reactions, hepatitis B reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity.
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, systemic vasculitis, deep vein thrombosis.
Most common (>=1%) Cataract, visual acuity reduced, macular edema, uveitis, conjunctival hemorrhage, eye pain, hypotony of eye, anterior chamber inflammation, dry eye, vitreous opacities, conjunctivitis, posterior capsule opacification, ocular hyperemia
Serious Cataract requiring surgery, elevated IOP with potential optic nerve damage and visual field defects, secondary ocular infection including herpes simplex, perforation of globe in patients with corneal or scleral thinning
Pharmacology
TNF-alpha antagonist; adalimumab-adaz is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, also lysing surface TNF-expressing cells in vitro in the presence of complement.
Corticosteroid; fluocinolone acetonide inhibits inflammatory responses by blocking phospholipase A2 via lipocortin induction, thereby suppressing prostaglandin and leukotriene synthesis and inhibiting edema, leukocyte migration, capillary proliferation, and fibroblast proliferation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Hyrimoz
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Yutiq
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Hyrimoz
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Yutiq
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Hyrimoz
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Yutiq
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Hyrimoz.
$25/fillfill
Yutiq Copay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HyrimozView full Hyrimoz profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.